

17 May 02
2002028595



162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number
WO 01/37846 A1

(51) International Patent Classification⁷: **A61K 31/726**

(21) International Application Number: **PCT/SE00/02313**

(22) International Filing Date:
23 November 2000 (23.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9904289-7 26 November 1999 (26.11.1999) SE

(71) Applicants and

(72) Inventors: **WADELL, Göran** [SE/SE]; Slädvägen 4,
S-903 39 Umeå (SE). **ARNBERG, Niklas** [SE/SE];
Kuratorvägen 19, S-907 36 Umeå (SE).

(74) Agent: **BERGENSTRÄHLE & LINDVALL AB**; P.O.
Box 17704, S-118 93 Stockholm (SE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,

DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHOD AND COMPOSITION FOR THE TREATMENT OF ADENOVIRAL OCULAR INFECTIONS**



(57) Abstract: Adenoviral infections and in particular ocular adenoviral infections, e.g. kerato-conjunctivitis, can be treated or alleviated by the administration of a substance, interfering with the interaction between the virus and the sialic acid receptor, in a therapeutically effective amount.

WO 01/37846 A1



ACTION